BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 24, 2003
View Archived Issues
Monitoring Committee Suspends Enrollment In QLT, Xenova Trial
QLT Inc. agreed to temporarily suspend enrollment in two Phase III studies of tariquidar in non-small-cell lung cancer patients on advice of a monitoring committee, which reportedly noted some toxicity in the study. (BioWorld Today)
Read More
BioMarin Raises $75M Publicly, Gets Good News On Aldurazyme
Read More
Two Interleukin Molecules, IL-12 & IL-23, Duke It Out To Nail Guilt Or Innocence In Mouse Autoimmunity
Read More
Nasdaq Market Looking To Ease Rules For Continued Listing
Read More
Other News To Note
Read More
Appointments And Advancements
Read More